Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Aspirin 81mg Chewable Tablets
NCT06655194Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin in thromboembolism (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration-time curve from time zero to the last non-zero concentration and Maximum observed concentration. Started Feb 2025; status: completed.
02
Drugs
aspirin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06655194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655194.